Morgane Milin1, Divi Cornec2, Myriam Chastaing3, Veronique Griner3, Sofian Berrouiguet3, Emmanuel Nowak4, Thierry Marhadour2, Alain Saraux2, Valérie Devauchelle-Pensec2. 1. Rheumatology Unit and Immunology Department (EA 2216), hôpital de la Cavale-Blanche, université Bretagne-Occidentale, CHU de Brest, BP 814, 29609 Brest cedex, France. Electronic address: morganemilin@hotmail.fr. 2. Rheumatology Unit and Immunology Department (EA 2216), hôpital de la Cavale-Blanche, université Bretagne-Occidentale, CHU de Brest, BP 814, 29609 Brest cedex, France. 3. Psychiatric Unit, université Bretagne-Occidentale, CHU de Brest, BP 814, 29609 Brest cedex, France. 4. Inserm CIC 0502, CHU de Brest, 29609 Brest cedex, France.
Abstract
OBJECTIVE: To compare quality of life (QoL), depression, anxiety, and fatigue in prospectively included patients with primary Sjögren's syndrome (pSS) or with sicca but no diagnosis of Sjögren's syndrome. METHODS: Patients undergoing a multidisciplinary evaluation at a single university center in Brest, France, for suspected pSS and having sicca symptoms were included prospectively between November 2006 and December 2013. The same standardized investigations were performed in all patients. pSS and sicca not due to pSS diagnoses were based on evaluating physician opinion. Each patient completed three validated questionnaires on QoL (SF-36), fatigue (MFI), depression and anxiety (HADS). RESULTS: Of the 95 included patients, 55 (57.9%) had pSS and 40 (42.1%) had sicca without pSS. Gender distribution, age, disease duration, and sicca symptoms were similar in the two groups. The pSS group had a significantly higher proportion of patients with abnormal objective tests for dryness (Schirmer's test and salivary flow rate). The SF-36, HADS, and MFI scores were similarly altered in the two groups. Anxiety was more common than depression in both groups. The most affected domains were vitality in the SF-36 and general/physical fatigue in the MFI. Extraglandular systemic involvement was not a major determinant of QoL alteration in patients with pSS. CONCLUSIONS: Sicca symptoms are associated with severe alterations in SF-36, HADS, and MFI scores regardless of objective test abnormalities and pSS diagnosis. Anxiety is more common than depression and should be taken into account when managing all patients with sicca symptoms.
OBJECTIVE: To compare quality of life (QoL), depression, anxiety, and fatigue in prospectively included patients with primary Sjögren's syndrome (pSS) or with sicca but no diagnosis of Sjögren's syndrome. METHODS:Patients undergoing a multidisciplinary evaluation at a single university center in Brest, France, for suspected pSS and having sicca symptoms were included prospectively between November 2006 and December 2013. The same standardized investigations were performed in all patients. pSS and sicca not due to pSS diagnoses were based on evaluating physician opinion. Each patient completed three validated questionnaires on QoL (SF-36), fatigue (MFI), depression and anxiety (HADS). RESULTS: Of the 95 included patients, 55 (57.9%) had pSS and 40 (42.1%) had sicca without pSS. Gender distribution, age, disease duration, and sicca symptoms were similar in the two groups. The pSS group had a significantly higher proportion of patients with abnormal objective tests for dryness (Schirmer's test and salivary flow rate). The SF-36, HADS, and MFI scores were similarly altered in the two groups. Anxiety was more common than depression in both groups. The most affected domains were vitality in the SF-36 and general/physical fatigue in the MFI. Extraglandular systemic involvement was not a major determinant of QoL alteration in patients with pSS. CONCLUSIONS: Sicca symptoms are associated with severe alterations in SF-36, HADS, and MFI scores regardless of objective test abnormalities and pSS diagnosis. Anxiety is more common than depression and should be taken into account when managing all patients with sicca symptoms.
Authors: John A Gonzales; Annie Chou; Jennifer R Rose-Nussbaumer; Vatinee Y Bunya; Lindsey A Criswell; Caroline H Shiboski; Thomas M Lietman Journal: Am J Ophthalmol Date: 2018-04-12 Impact factor: 5.258
Authors: Guillermo Carvajal Alegria; Pierre Gazeau; Sophie Hillion; Claire I Daïen; Divi Y K Cornec Journal: Clin Rev Allergy Immunol Date: 2017-10 Impact factor: 8.667
Authors: Sara S McCoy; Christie M Bartels; Ian J Saldanha; Vatinee Y Bunya; Esen K Akpek; Matthew A Makara; Alan N Baer Journal: J Rheumatol Date: 2020-09-15 Impact factor: 5.346